Studying a new therapeutic approach for HER2+ breast cancer

Despite the considerable progress made in the development of new therapies, breast cancer remains the most common cause of cancer-related death in women in Germany. New treatment options are therefore needed, thus prompting scientists to continuously investigate alternative approaches. Researchers at the Leibniz Research Centre for Working Environment and Human Factors (IfADo) have already shown that the enzyme EDI3 is associated with changes in the metabolism of cancer cells. The team now focuses on the potential of EDI3 as a therapeutic target in a specific breast cancer subgroup. This new project will be funded by the Deutsche Krebshilfe.